Literature DB >> 16426904

Pulmonary infection in mild variant cystic fibrosis: implications for care.

A Lording1, J McGaw, A Dalton, G Beal, M Everard, C J Taylor.   

Abstract

BACKGROUND: Disease phenotype in cystic fibrosis (CF) shows considerable heterogeneity. Atypical or mild mutations in the CFTR gene have been linked to late-onset pulmonary disease; however, few reports document the condition of the airway in infants and young children with apparent "mild" disease. Prognosis is uncertain in this group of patients and this, in turn, has led to inconsistency in management. Our initial experience of pulmonary infection in children with mild variant CF prompted a more detailed review of clinical outcome.
METHODS: A retrospective cohort study was carried out comparing frequency of bacterial isolates and clinical outcomes in eleven compound heterozygotes for DeltaF508 and a second mild mutation, mainly R117H, with a matched group of DeltaF508 homozygotes.
RESULTS: Staphylococcus aureus was isolated in 8 of the 11 patients with mild variant disease and Pseudomonas aeruginosa found in 7 (64%), although the frequency of positive cultures was significantly less (2.8/year) than the DeltaF508 homozygotes (6.1/year, p<0.05). Shwachman scores (median+range) were significantly higher in patients with mild mutations - 94, 74-92 vs. 88, 77-91; p<0.005); there was also a small but significant difference in chest radiograph (Chrispin-Norman) scores (median+range) (mild 5.1, 4-9, vs. severe 5.8, 3-10; p 0.04). There was little difference in lung function in terms of FEV1 (median+range) between the two groups (% predicted, mild 86.5, 68-87 vs. severe 76.0, 65-88; p 0.5).
CONCLUSIONS: Most patients with mild variant CF will have bacterial isolates from airway cultures requiring antibiotic therapy three to four times a year. Infection with both S. aureus and P. aeruginosa is common. Anti-staphylococcal prophylaxis for the first two years should be considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426904     DOI: 10.1016/j.jcf.2005.11.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  6 in total

1.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

Authors:  Drucy Borowitz; Richard B Parad; Jack K Sharp; Kathryn A Sabadosa; Karen A Robinson; Michael J Rock; Philip M Farrell; Marci K Sontag; Margaret Rosenfeld; Stephanie D Davis; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

Review 2.  Newborn screening for cystic fibrosis.

Authors:  Jack K Sharp; Michael J Rock
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

3.  Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity.

Authors:  Sebastián A Riquelme; Benjamin D Hopkins; Andrew L Wolfe; Emily DiMango; Kipyegon Kitur; Ramon Parsons; Alice Prince
Journal:  Immunity       Date:  2017-12-12       Impact factor: 31.745

Review 4.  Association of CFTR gene mutation with bronchial asthma.

Authors:  Nutan Maurya; Shally Awasthi; Pratibha Dixit
Journal:  Indian J Med Res       Date:  2012-04       Impact factor: 2.375

5.  Evolution of metabolic divergence in Pseudomonas aeruginosa during long-term infection facilitates a proto-cooperative interspecies interaction.

Authors:  Charlotte Frydenlund Michelsen; Seyed Mohammad Hossein Khademi; Helle Krogh Johansen; Hanne Ingmer; Pieter C Dorrestein; Lars Jelsbak
Journal:  ISME J       Date:  2015-12-18       Impact factor: 10.302

6.  Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.

Authors:  Anne Munck; Dominique Delmas; Marie-Pierre Audrézet; Lydie Lemonnier; David Cheillan; Michel Roussey
Journal:  J Med Screen       Date:  2017-04-28       Impact factor: 2.136

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.